Search Site

BP announces $7bn gas project

The project aims to unlock 3 trillion cu ft of gas resources in Indonesia.

Lulu Retail Q3 profit $35m

For the nine-month period, net profit increased by 73.3%.

Talabat IPO offer price range announced

The subscription will close on 27 Nov for UAE retail investors.

Salik 9M net profit $223m

The company's third-quarter profit increased by 8.8 percent.

Avia to buy 40 Boeing aircraft

The transaction for the purchase of 737 MAX 8 jets valued at $4.9bn.

Covid cases up 80 percent globally as new subvariant rises

Several countries in the Northern Hemisphere, including the US, UK, France and Japan have seen a summer uptick in cases in recent weeks. (AFP)
  • The UN agency said that nations reported nearly 1.5 million new cases from July 10 to August 6.
  • Many of the new cases came in the Western Pacific region, which saw infections jump by 137 percent.

PARIS, FRANCE – The number of new COVID-19 cases reported worldwide rose by 80 percent in the last month, the World Health Organization said on Friday, days after designating a new “variant of interest”.

The WHO declared in May that Covid is no longer a global health emergency, but has warned that the virus will continue to circulate and mutate, causing occasional spikes in infections, hospitalizations and deaths.

In its weekly update, the UN agency said that nations reported nearly 1.5 million new cases from July 10 to August 6, an 80 percent increase compared to the previous 28 days.

However the number of deaths fell by 57 percent to 2,500.

The WHO warned that the reported number of cases and deaths do not reflect the true numbers, in part because countries carry out far less testing and monitoring than during earlier stages of the pandemic.

Many of the new cases came in the Western Pacific region, which saw infections jump by 137 percent, the WHO said.

Several countries in the Northern Hemisphere, including the US, UK, France and Japan have seen a summer uptick in cases in recent weeks.

Experts have suggested that summer gatherings and travel, declining immunity and a new subvariant may have all played a role in the increase.

On Wednesday, the WHO designated the Omicron subvariant EG.5 as a “variant of interest” following a steady rise in its prevalence.

More than 17 percent of all reported cases were EG.5 in mid-July, up from 7.6 percent a month before, according to the WHO.

  Subvariant poses ‘low’ risk

EG.5, which has been unofficially nicknamed “Eris” online, is considered to be a descendant of the XBB lineage of the virus.

It seems to be more transmissible than other circulating variants, likely due to a mutation in its spike protein, and the WHO said it has shown an ability to evade immunity.

But there is no sign that EG.5 causes more severe Covid symptoms and it poses a “low” risk to global public health, the WHO said, comparing its threat to other recent Omicron subvariants.

Nonetheless, WHO chief Tedros Adhanom Ghebreyesus warned that “the risk remains of a more dangerous variant emerging that could cause a sudden increase in cases and deaths”.

France’s Health Minister Aurelien Rousseau called for vigilance, while emphasizing that Covid numbers remain at low levels.

“We will have to live with the resurgence of this virus for several seasons to come,” he said in a statement sent to AFP.

Antoine Flahault, director of the Institute of Global Health at the University of Geneva, told AFP that the true Covid situation remained unclear “just about everywhere in the world”.

“Health authorities urgently need to reinstate a reliable Covid health monitoring system,” he said, calling for wastewater to be analysed to detect virus trends.

While the impact of Covid has been greatly diminished due to high levels immunity from either vaccination or prior infection, the virus still poses a threat – including long Covid, for which symptoms can last for months or years.

The WHO has urged countries to ramp up vaccination efforts.

Pharmaceutical firms Pfizer/BioNTech, Moderna and Novavax are all working on updating their Covid vaccines to target XBB subvariants.